Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.62
(-8.47%)
SEK 1.62
(-8.47%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.82 Million SEK | -25.11% |
| 2022 | 10.45 Million SEK | -21.09% |
| 2021 | 13.24 Million SEK | 447.4% |
| 2020 | 2.42 Million SEK | -29.94% |
| 2019 | 3.45 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | -100.0% |
| 2015 | 388.00 SEK | -99.53% |
| 2014 | 82 Thousand SEK | -94.59% |
| 2013 | 1.51 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 6.93 Million SEK | -11.36% |
| 2023 Q4 | 7.82 Million SEK | -4.75% |
| 2023 Q3 | 8.21 Million SEK | -12.26% |
| 2023 FY | 7.82 Million SEK | -25.11% |
| 2023 Q1 | 9.84 Million SEK | -5.86% |
| 2023 Q2 | 9.36 Million SEK | -4.82% |
| 2022 Q1 | 12.68 Million SEK | -4.24% |
| 2022 Q4 | 10.45 Million SEK | -5.74% |
| 2022 Q2 | 12.38 Million SEK | -2.39% |
| 2022 FY | 10.45 Million SEK | -21.09% |
| 2022 Q3 | 11.09 Million SEK | -10.43% |
| 2021 FY | 13.24 Million SEK | 447.4% |
| 2021 Q2 | 2.13 Million SEK | 7.57% |
| 2021 Q3 | 1.86 Million SEK | -12.62% |
| 2021 Q1 | 1.98 Million SEK | -18.1% |
| 2021 Q4 | 13.24 Million SEK | 611.06% |
| 2020 Q2 | 3.03 Million SEK | -3.43% |
| 2020 FY | 2.42 Million SEK | -29.94% |
| 2020 Q4 | 2.42 Million SEK | -11.36% |
| 2020 Q3 | 2.73 Million SEK | -10.17% |
| 2020 Q1 | 3.14 Million SEK | -8.89% |
| 2019 Q4 | 3.45 Million SEK | 53.51% |
| 2019 FY | 3.45 Million SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q2 | 2.76 Million SEK | 0.0% |
| 2019 Q3 | 2.25 Million SEK | -18.57% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | -100.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | 388.00 SEK | -99.53% |
| 2014 FY | 82 Thousand SEK | -94.59% |
| 2013 FY | 1.51 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | 51.37% |
| Ziccum AB (publ) | 857 Thousand SEK | -813.419% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -57.22% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 68.033% |
| Genovis AB (publ.) | 79.32 Million SEK | 90.131% |
| Intervacc AB (publ) | 181 Thousand SEK | -4224.862% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | 62.02% |
| Active Biotech AB (publ) | 3 Million SEK | -160.933% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 87.019% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -56.56% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 89.038% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -1746.226% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 92.792% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -154.984% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -203.411% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -682.8% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 99.201% |
| Camurus AB (publ) | 24.5 Million SEK | 68.058% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 71.603% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 99.097% |
| Cyxone AB (publ) | 858 Thousand SEK | -812.354% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -357.51% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 78.733% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -1075.375% |
| SynAct Pharma AB | 637 Thousand SEK | -1128.885% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -820.941% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -344.52% |
| BioInvent International AB (publ) | 23.24 Million SEK | 66.322% |
| Alzinova AB (publ) | 800 Thousand SEK | -878.5% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 92.649% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -912.573% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 91.373% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 74.478% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 96.618% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -637.795% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |